Personalizing Treatment and Managing Patient Concerns

Drs. Bradley Monk and Robert Coleman examine practical issues to consider in managing toxicities associated with antiangiogenic agents: dealing with side effects of first-line versus palliative treatment, the possibility of dose reduction to alleviate toxicities, risk factors for catastrophic side effects such as RPLS and GI perforation, and whether patients with serious side effects can be re-treated when these events have resolved. They also address the role of sensitivity tests and molecular profiling in determining treatment.